Danaher (DHR) Stock Price, News & Analysis

Company Overview

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Key Stats

• Today's Range: $202.66 to $206.39
• 50-Day Range: $184.79 to $205.60
• 52-Week Range: $171.00 to $281.70
• Volume: 5.36 million shs
• Average Volume: 3.97 million shs
• Market Capitalization: $147.22 billion
• P/E Ratio: 43.74
• Dividend Yield: 0.62%
• Price Target: $247.61
• Consensus Rating: Moderate Buy

Danaher Stock Analysis - MarketRank™

Danaher scored higher than 97% of companies evaluated by MarketBeat, and ranked 43rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Danaher has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 17 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Danaher has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.32%

Earnings Growth

Earnings for Danaher are expected to grow by 12.32% in the coming year, from $7.63 to $8.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Danaher is 43.74, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.03.

Price to Earnings Ratio vs. Sector

The P/E ratio of Danaher is 43.74, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.41.

Price to Earnings Growth Ratio

Danaher has a PEG Ratio of 2.86. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Danaher has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.21% of the float of Danaher has been sold short.

Short Interest Ratio / Days to Cover

Danaher has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Danaher has recently increased by 1.94%, indicating that investor sentiment is decreasing.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Danaher has a dividend yield of 0.62%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Danaher has only been increasing its dividend for 2 years.

Dividend Coverage

The dividend payout ratio of Danaher is 27.23%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Danaher will have a dividend payout ratio of 14.94% next year. This indicates that Danaher will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.45

Percentage of Shares Shorted

1.21% of the float of Danaher has been sold short.

Short Interest Ratio / Days to Cover

Danaher has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Danaher has recently increased by 1.94%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.96

News Sentiment

Danaher has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 82 news articles for Danaher this week, compared to 32 articles on an average week.

Search Interest

51 people have searched for DHR on MarketBeat in the last 30 days. This is an increase of 292% compared to the previous 30 days.

MarketBeat Follows

7 people have added Danaher to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Danaher insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $249,054,390.00 in company stock.

Percentage Held by Insiders

11.10% of the stock of Danaher is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.05% of the stock of Danaher is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DHR Stock Analysis - Frequently Asked Questions

How have DHR shares performed this year?

Danaher's stock was trading at $229.55 at the beginning of 2025. Since then, DHR shares have decreased by 10.4% and is now trading at $205.6010.

How were Danaher's earnings last quarter?

Danaher Corporation (NYSE:DHR) announced its quarterly earnings results on Tuesday, July, 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The company's revenue for the quarter was up 3.4% compared to the same quarter last year.
Read the conference call transcript.

Does Danaher have any subsidiaries?

Danaher subsidiaries include Aldevron, Precision NanoSystems, Aquatic Informatics, Cytiva, GE Biopharma, Integrated DNA Technologies, IDBS Group, and others.

Who are Danaher's major shareholders?

Top institutional investors of Danaher include Montrusco Bolton Investments Inc. (0.25%), Blair William & Co. IL (0.19%), Mirova US LLC (0.16%) and Aberdeen Group plc (0.16%). Insiders that own company stock include Steven M Rales, Alan G Spoon, Rainer Blair, Joakim Weidemanis, Linda Filler, Daniel Raskas, Matthew Mcgrew, Brian W Ellis, Teri List, Christopher Paul Riley, Walter G Lohr, Raymond C Stevens, Jennifer Honeycutt, Jose-Carlos Gutierrez-Ramos and Georgeann Couchara.
View institutional ownership trends.

How do I buy shares of Danaher?

Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Danaher own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Danaher investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), UnitedHealth Group (UNH), BlackRock (BLK), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

• Record date for 7/25 Dividend: 6/27/2025
• Last Earnings: 7/22/2025
• Dividend Payable: 7/25/2025
• Today: 7/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Industrial Conglomerates
• Current Symbol: NYSE:DHR
• CIK: 313616
• Web: www.danaher.com
• Phone: (202) 828-0850
• Fax: 202-828-0860
• Employees: 63,000
• Year Founded: 1984

Price Target and Rating

• Average Price Target for Danaher: $247.61
• High Price Target: $315.00
• Low Price Target: $205.00
• Potential Upside/Downside: +20.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.70
• Trailing P/E Ratio: 43.74
• Forward P/E Ratio: 26.95
• P/E Growth: 2.86
• Net Income: $3.90 billion
• Net Margins: 14.21%
• Pretax Margin: 16.97%
• Return on Equity: 10.70%
• Return on Assets: 6.85%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 1.62
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $23.88 billion
• Price / Sales: 6.17
• Cash Flow: $10.93 per share
• Price / Cash Flow: 18.81
• Book Value: $73.10 per share
• Price / Book: 2.81

Miscellaneous

• Outstanding Shares: 716,050,000
• Free Float: 636,570,000
• Market Cap: $147.22 billion
• Optionable: Optionable
• Beta: 0.77